Introduction {#s1}
============

Polycystic ovary syndrome (PCOS) expression, under the influence of multiple pathogenic mechanisms, presents hyperandrogenism, hyperinsulinemia, obesity and insulin resistance (IR) as the most prevalent findings \[[@R01], [@R02]\]. Several markers of IR have been tested. An alternative marker for IR and beta-cell dysfunction, the connecting peptide (Pep-C), facilitates the assembly, folding and processing of insulin and is secreted in an equimolar ratio with this hormone from the pancreatic beta cell directly into the portal circulation \[[@R03]\]. As advantages, the C-peptide does not undergo hepatic first-pass metabolism and has a longer half-life than insulin. Therefore, its concentration in the blood is more stable, providing an accurate marker of pancreatic insulin secretion \[[@R04]\]. An increase in its levels suggests a worsened insulin resistant state.

C-peptide, initially considered an inactive molecule, has, currently, been shown to be a bioactive molecule that binds to the surface of several cell types, where it activates the calcium-dependent intracellular signalling pathway \[[@R05]\]. In patients with type 1 diabetes mellitus (T1DM), C-peptide seems to have a protective effect on microvascular complications, prevents or decreases diabetes-induced glomerular changes and has an anti-inflammatory effect \[[@R06]\]. On the other side, a few studies suggest that high levels of C-peptide promote atherogenesis \[[@R07]\]. Further, in type 2 diabetes mellitus (T2DM), C-peptide has some pro-inflammatory properties in the process of atherosclerotic plaque formation, may induce vascular smooth muscle cell proliferation and has also been associated with the intima-media thickness of the carotid artery \[[@R07], [@R08]\]. A relationship between C-peptide concentrations and macrovascular complications in T2DM was also reported \[[@R9]\]. Additional data suggest that C-peptide might participate in the vascular inflammatory response and contribute to the development of cardiovascular disease (CVD) \[[@R10]\]. Whether C-peptide compares to other known biomarkers of insulin resistance in predicting future CVD or not is still a matter of debate \[[@R10], [@R11]\].

Currently, in the clinical setting, the C-peptide measurement has been limited to differentiating T1DM and T2DM, the identification of patients with maturity-onset diabetes of the young (MODY), the detection of absolute insulin deficiency, and monitoring pancreatic beta-cell function \[[@R12]\]. The role of C-peptide in predicting CVD in PCOS patients remains limited to helping to determine the degree of insulin resistance and β-cell function. The current study hypothesized that the fasting C-peptide concentration could be a useful marker of dysmetabolic and hormonal alterations in PCOS patients. This hypothesis was tested by comparing head-to-head fasting C-peptide to other already established clinical and biochemical predictors of future T2DM and CVD in PCOS patients.

Methods {#s2}
=======

The study enrolled 385 PCOS patients and 240 normal cycling women who attended at the Julio Muller University Hospital and Tropical Institute of Reproductive Medicine in Cuiaba, MT, Brazil, from January 2012 to December 2016, who had C-peptide measured in blood. Every patient gave full-informed written consent by signing a form approved by the local Committee for Ethics in Research. Presences of infrequent bleeding, amenorrhea, clinical or biochemical hyperandrogenism, and polycystic ovary morphology were investigated and PCOS was diagnosed using the Rotterdam criteria \[[@R13]\]. The criteria used to exclude other hyperandrogenic conditions were as follows: non-classic 21-hydroxylase deficiency (17-hydroxyprogesterone ≤ 5 ng/mL), 11β-hydroxylase deficiency (11-deoxycortisol \< 8 ng/mL), 3β-hydroxysteroid dehydrogenase deficiency (17-hydroxypregnenolone \< 0.42 ng/mL), hyperprolactinemia (prolactin (PRL) \< 25 ng/mL) and thyroid dysfunction (thyroxin stimulating hormone 0.35 - 4.2 µg/dL) \[[@R14], [@R15]\]. Users of sex steroids or insulin-sensitizing agents over the last 6 months were also excluded.

Waist circumference (WC), hip circumference (H), body weight (BW), body mass index (BMI), lean body mass (LBM), fat mass (FM), and conicity index (CI) measurement procedures were detailed in a previous study \[[@R16]\]. A BMI lower than 25 was considered a normal weight, 25 - 29.9 was considered overweight, and 30 kg/m^2^ or higher was defined as obese \[[@R17]\]. The visceral adiposity index (VAI) was estimated using the equation: WC/(36.58 + (1.89 × BMI)) × (TG/0.81) × (1.52/HDL-c) \[[@R18]\].

For all of the biochemical and hormonal measurements, blood samples were collected between the third and fifth days of a spontaneous menstrual flow or in the case of amenorrhea at any day; in this case, the progesterone (P4) level was measured to certify that samples were collected in the follicular phase, and, in this case, the results were validated whenever the P4 levels were ≤ 2.0 ng/mL \[[@R14]\]. A chemiluminescence assay (Advia Centaur, Siemens Healthcare Diagnostics, UK) with a sensitivity of 0.21 ng/mL, the coefficients of intra- and inter-assay variation were between 3.7-12.4% and 2.6-3.9% was used to measure P4. C-peptide was measured using a chemiluminescence assay (Elecsys 1010, Roche Diagnostics GmbH, Mannhein, German) with a sensitivity of 0.01 ng/mL and intra- and inter-assay coefficients of variation between 3% and 5% in all of the concentration ranges. Sensitivity, working-range, and imprecision of other hormone measurements at the local laboratory were given elsewhere \[[@R16]\]. A hyperandrogenic state was defined when FAI was ≥ 6%, the total testosterone was ≥ 2.08 nmol/L, DHEAS was 6.7 nmol/L, A was ≥ 8.7 nmol/L, and the free T was ≥ 0.027 pmol/L \[[@R14]\].

Glucose oxidase technique (Beckman glucose Analyses, Fullerton, CA, USA) was used to measure fasting glucose. Glycated hemoglobin was measured using the turbidimetric assay (Wiener Laboratories, Rosario, Argentina). Impaired fasting glucose (IFG) was defined by a fasting plasma glucose (FPG) concentration of \> 100 mg/dL (5.5 mmol/L) and \< 126 mg/dL (6.99 mmol/L). Insulin resistance was defined by fasting insulin levels of \> 12.2 µU/mL \[[@R19]\] and/or an HOMA-IR of ≥ 2.7 \[[@R20]\]. HOMA-IR, HOMA %B and HOMA S were calculated using the free HOMA 2 calculator software (Diabetes Trials Unit, Oxford, UK) \[[@R21]\]. Fasting β cell responsiveness to glucose concentrations was estimated using the fasting C-peptide/fasting glucose ratio \[[@R22]\]. Hepatic insulin extraction was computed in the basal state as the molar ratio of the C-peptide to the insulin levels \[[@R04]\]. Total cholesterol (TC), triglycerides (TG), and high-density lipoprotein cholesterol (HDL-c) were measured using an enzymatic assay (Wiener Laboratories, Rosario, Argentina). Low-density lipoprotein cholesterol (LDL-c) was calculated as follows: CT (HDL-C + TG/5) \[[@R23]\]. Lipid accumulation product (LAP) was calculated using (WC (cm) - 58) × (TG (mmol/L)) \[[@R24]\].

The original data of each variable were initially submitted to the Grub's test to avoid the interference of outliers. After exclusion of the outlier data, the distribution was assessed by a Shapiro-Wilk test and those with a non-Gaussian distribution were transformed. The data that skewed to the right were linearized using a logarithmic transformation, and the data that skewed to the left were linearized using the square transformation. Prior to the analysis, the data were back-transformed into the original units. The results are presented as the mean and standard error of the mean (SEM). Differences between the two independent and continuous variables were assessed using Welch test. The relationship between the two variables was examined using the Pearson's correlation coefficient (r). A stepwise-multiple regression analysis was performed with C-peptide as the criterion variable and several anthropometric, endocrine, and metabolic variables as predictor variables. The decision for a predictive variable to be included in the model was P ≤ 0.05 in the simple linear correlation. All of the statistical procedures were performed with SPSS version 17 (SPSS Inc., Chicago, IL, USA). P-values \< 0.05 were considered statistically significant.

Results {#s3}
=======

As whole groups, the PCOS patients and the normal cycling women were, on average, 27.3 ± 5.4 and 30.2 ± 4.9 years old, respectively (P \< 0.001). Regarding PCOS patients, 116 (30.1%) were of a normal weight, 120 (31.2%) were overweight, and 149 (38.7%) were obese. Among controls, 61.3% were normal weight, 29% were overweight, and 9.7% were obese. The number of obese was significantly higher in PCOS (P \< 0.001). A total of 279 (72.5%) PCOS patients had biochemical hyperandrogenism and 106 (27.5%) had normal androgen levels. In normal cycling women, no one presented biochemical hyperandrogenism. IFG was found in 15.2% of the PCOS patients and in 3.9% of controls (P \< 0.001). Insulin resistance was present in 48.7% of the PCOS patients and in 11.6% of control patients (P \< 0.001). The baseline clinical, anthropometric, metabolic, and hormonal characteristics of PCOS patients and normal cycling women are compared in [Table 1](#T1){ref-type="table"}. The simple correlation of several independent variables with C-peptide concentrations is presented in [Table 2](#T2){ref-type="table"}. The blood pressures, both the systolic and diastolic values, were significantly correlated with C-peptide in PCOS (P \< 0.001) but not in controls (P \> 0.05). Using univariate linear regression of C-peptide with several anthropometrical variables (body weight, BMI, WC, W/H ratio, CI and VAI), remarkable correlations were found (P \< 0.001 for all). FM and LBM were also significantly correlated with C-peptide concentrations in both groups.

###### Clinical, Metabolic and Hormonal Baseline Characteristics of Normal Cycling Women and Polycystic Ovary Syndrome Patients

  Variables                 Control   PCOS    P\*              
  ------------------------- --------- ------- -------- ------- ----------
  Clinical                                                     
    SBP (mm Hg)             114.07    0.59    117.90   0.61    \< 0.001
    DBP (mm Hg)             73.25     0.55    75.56    0.54    0.002
  Anthropometrical                                             
    Body weight (kg)        63.57     0.75    74.76    0.87    \< 0.001
    BMI (kg/m^2^)           24.51     0.30    29.00    0.33    \< 0.001
    WC (cm)                 73.51     0.59    85.79    0.75    \< 0.001
    W/H ratio               0.74      0.00    0.79     0.00    \< 0.001
    CI                      1.07      0.00    1.15     0.00    \< 0.001
    FM (kg)                 19.85     0.51    28.69    0.62    \< 0.001
    LBM (kg)                43.49     0.34    36.68    0.41    \< 0.001
    VAI                     0.76      0.03    2.43     0.11    \< 0.001
  Metabolic                                                    
    Glucose (nmol/L)        4.67      0.03    5.00     0.03    \< 0.001
    Insulin (µmol/L)        50.91     2.34    97.92    3.36    \< 0.001
    HbA1C (%)               4.99      0.03    5.80     0.15    \< 0.001
    C-peptide (nmol/L)      0.54      0.01    0.77     0.02    \< 0.001
    C-pep/glucose ratio     0.11      0.00    0.015    0.00    \< 0.001
    Insulin/C-pep ratio     104.88    4.83    130.87   3.45    \< 0.001
    C-pep/insulin ratio     0.02      0.01    0.002    0.001   \<0.001
    LAP                     15.73     0.99    47.02    2.62    \< 0.001
    HOMA-IR                 0.98      0.04    1.82     0.06    \< 0.001
    HOMA %B                 103.39    3.17    137.96   2.95    \< 0.001
    HOMA S                  138.13    5.86    80.54    2.86    \< 0.001
    TC (mmol/L)             4.33      0.54    4.69     0.50    0.624
    TG (mmol/L)             0.93      0.02    1.60     0.13    \< 0.001
    HDL (\< 0.001 mmol/L)   1.46      0.06    1.18     0.01    \< 0.001
    LDL-c (mmol/L)          2.58      0.09    2.91     0.07    0.004
    VLDL-c (mmol/L)         0.45      0.01    0.62     0.02    \< 0.001
  Hormonal                                                     
    Testo T (nmol/L)        1.05      0.03    1.95     0.04    \< 0.001
    Free T (pmol/L)         0.01      0.00    0.04     0.00    \< 0.001
    FAI (%)                 2.17      0.12    6.93     0.27    \< 0.001
    FEI (%, pg/nmol)        0.53      0.01    0.66     0.02    \< 0.001
    E2 (pmol/L)             177.92    6.60    242.75   10.15   \< 0.001
    17-OHP4 (nmol/L)        2.59      0.08    3.65     0.11    \< 0.001
    PRL (pmol/L)            695.91    25.56   571.66   15.51   \< 0.001

PCOS: polycystic ovary syndrome. \*Pearson's correlation coefficient.

###### Simple Correlation Between C-Peptide and Selected Clinical, Anthropometrical, Hormonal and Metabolic Cardiovascular Risk Markers in Polycystic Ovary Syndrome and Normal Cycling Women

  Variables               PCOS     Control            
  ----------------------- -------- --------- -------- -------
  Clinical                                            
    SBP (mm Hg)           0.314    0.000     0.016    0.808
    DBP (mm Hg)           0.265    0.000     0.072    0.285
  Anthropometrical                                    
    Body weight (kg)      0.509    0.000     0.356    0.000
    BMI (kg/m^2^)         0.581    0.000     0.332    0.000
    WC (cm)               0.565    0.000     0.428    0.000
    W/H ratio             0.459    0.000     0.258    0.000
    CI                    0.353    0.000     0.240    0.000
    FM (kg)               0.549    0.000     0.376    0.000
    LBM (kg)              0.311    0.000     0.267    0.000
    VAI                   0.539    0.000     0.317    0.000
  Metabolic                                           
    Glucose (nmol/L)      0.381    0.000     0.294    0.000
    Insulin (µmol/L)      0.602    0.000     0.621    0.000
    HbA1C (%)             0.351    0.000     0.187    0.007
    C-peptide (nmol/L)    \-       \-        \-       \-
    C-pep/glucose ratio   0.967    0.000     0.974    0.000
    Insulin/C-pep ratio   -0.164   0.002     -0.231   0.002
    C-pep/insulin ratio   0.167    0.001     0.234    0.002
    LAP                   0.434    0.000     0.433    0.000
    HOMA-IR               0.592    0.000     0.630    0.000
    HOMA %B               0.445    0.000     0.387    0.000
    HOMA S                -0.543   0.000     -0.517   0.000
    TC (mmol/L)           0.218    0.000     0.041    0.537
    TG (mmol/L)           0.452    0.000     0.271    0.000
    HDL (mmol/L)          -0.349   0.000     -0.097   0.144
    LDL-c (mmol/L)        0.119    0.027     -0.007   0.920
    VLDL-c (mmol/L)       0.418    0.000     0.404    0.000
  Hormonal                                            
    Testo T (nmol/L)      0.182    0.000     0.018    0.782
    Free F (pmol/L)       0.322    0.000     0.146    0.027
    FAI (%)               0.457    0.000     0.250    0.000
    E2 (pmol/L)           0.146    0.009     0.076    0.275
    FEI (%, pg/nmol)      0.517    0.00      0.421    0.000
    17-OHP4 (nmol/L)      -0.036   0.486     -0.079   0.238
    PRL (pmol/L)          -0.191   0.000     0.115    0.087

PCOS: polycystic ovary syndrome. \*Pearson's correlation coefficient.

All markers of dysglycemia were also correlated with C-peptide in both PCOS patients and normal cycling controls ([Table 2](#T2){ref-type="table"}). Ratios between C-peptide and insulin were weakly but significantly correlated (P \< 0.05), but fasting C-peptide/fasting glucose ratio (fasting β cell responsiveness) was highly and equally correlated in PCOS (r = 0.967, P \< 0.001) and controls (r = 0.974, P \<0.001). The LAP was moderately correlated with C-peptide levels in both groups. All of the lipids were also correlated with the C-peptide levels in PCOS but in normal cycling women, C-peptide was correlated only with TG and VLDL ([Table 2](#T2){ref-type="table"}). Total T, free testosterone and FAI were strongly correlated with C-peptide concentrations in PCOS patients. In controls, C-peptide was correlated with free T and FAI but not with total T. Estradiol and PRL levels were correlated with C-peptide only in PCOS subjects.

In normal cycling women, the importance of these correlations for the clarification of the role of C-peptide as marker of CVD risk was initially examined using a stepwise multiple regression with the inclusion of the significant simple correlation variables as predictors of C-peptide levels. The significant emerged model retained C-peptide/glucose ratio, fasting glucose, and VAI as strong predictors of C-peptide ([Table 3](#T3){ref-type="table"}). This table shows that fasting C-peptide/glucose ratio was the single best predictor and glucose and VAI were the next best predictors of the criterion variable. So, C-peptide/glucose ratio as shown in model 1 ([Table 3](#T3){ref-type="table"}) accounted for 93.5% of the predictor variance. The inclusion of glucose and VAI into models 2 and 3 resulted in an additional 6.8% of the variance being explained as shown in the column R^2^ change of [Table 3](#T3){ref-type="table"}. Therefore, the final model accounted for 99.3% of the variance (adjusted R^2^ = 0.993) and data indicated the strength of the model (adjusted R^2^ = 0.993, F = 38.33%, P \< 0.001). The non-standardized beta coefficients in the model 3 resulted in the following equation: C-peptide = -0.503 + 4.763 C-peptide/glucose ratio + 0.104 glucose + 0.011 VAI.

###### Stepwise Multiple Correlation Between C-Peptide and Known Predictors of Dysmetabolic Disease in Normal Cycling Women

  Model   R                                       R^2^    Adjusted R^2^   Standard error of estimate   Change statistics   Sig. F change   Durbin- Watson   
  ------- --------------------------------------- ------- --------------- ---------------------------- ------------------- --------------- ---------------- -------
  1       0.962[a](#nt103){ref-type="table-fn"}   0.926   0.925           0.058021                     0.935               962.028         0.000            
  2       0.996^b^                                0.993   0.993           0.017985                     0.068               5,368.995       0.000            
  3       0.997^c^                                0.994   0.993           0.173384                     0.000               3,833.105       0.000            1.979

Predictor: (constant), fasting C-peptide/glucose ratio. ^b^Predictor: (constant), fasting C-peptide/glucose ratio, glucose. ^c^Predictor: (constant), fasting C-peptide/glucose ratio, glucose, VAI.

In PCOS, the stepwise multiple regression with the inclusion of the significant simple correlated variables as selected predictors of C-peptide levels, demonstrated that a significant model emerged from this examination, and the fasting C-peptide/glucose ratio, the fasting glucose, body weight, and FEI were retained as strong predictors of C-peptide ([Table 4](#T4){ref-type="table"}). In the final model, the inclusion of the fasting C-peptide/glucose ratio accounted for 97.4% of the C-peptide variance (adjusted r^2^ = 0.949). The inclusion of the fasting glucose, body weight, and FEI in the final model explained an additional 3.9% of the C-peptide variance (r^2^ change = 0.001). Therefore, the final model accounted for 98.8% of the variance in the criterion variable (F = 7.161, P = 0.000, adjusted r^2^ = 0.988). The non-standardized beta coefficient of each variable resulted in the following equation: C-peptide= -0.722 + 5.148 C-peptide/glucose ratio + 0.159 glucose - 0.001 body weight.

###### Stepwise Multiple Regression Between C-Peptide and Known Predictors of Dysmetabolic Disease in Patients With Polycystic Ovary Syndrome

  Model   R                                       R^2^    Adjusted R^2^   Standard error of estimate   Change statistics   Sig. F change   Durbin- Watson   
  ------- --------------------------------------- ------- --------------- ---------------------------- ------------------- --------------- ---------------- -------
  1       0.974[a](#nt104){ref-type="table-fn"}   0.950   0.949           96.09569                     0.950               2,884.299       0.000            
  2       0.994^b^                                0.987   0.987           48.64369                     0.038               445.099         0.000            
  3       0.994^c^                                0.988   0.988           47.50930                     0.001               8.345           0.004            
  4       0.994^d^                                0.988   0.988           46.56880                     0.001               7.161           0.008            2.031

Predictor: (constant), fasting C-peptide/glucose ratio. ^b^Predictor: (constant), fasting C-peptide/glucose ratio, glucose. ^c^Predictor: (constant), fasting C-peptide/glucose ratio, glucose, body weight. ^d^Predictor: (constant), fasting C-peptide/glucose ratio, glucose, body weight, FEI.

Discussion {#s4}
==========

C-peptide is considered to be a more reliable marker of pancreatic insulin-secretion, and the current study re-examined and expanded on previous knowledge regarding the use of C-peptide as a potential metabolic biomarker of CVD risk in PCOS patients. C-peptide presented a strong correlation with other established markers of risk for vascular and metabolic diseases in the current study. To the best of our knowledge, there are no studies including clear clinical parameters on the investigation of the role of C-peptide in the development of CVD and T2DM in PCOS women. In the present study, blood pressures were strongly correlated with C-peptide concentrations in the whole group of PCOS patients. A few studies have demonstrated that C-peptide predicts the future development of dysmetabolic diseases in both non-PCOS and PCOS patients \[[@R25], [@R26]\]. The increased concentration of C-peptide in PCOS reflects an increased pancreatic β-cell function \[[@R02]\]. Moreover, in addition to insulin resistance, pancreatic β-cell dysfunction, reflected by C-peptide levels, is yet considered the second important risk factor to predict T2DM in PCOS \[[@R27]\]. As far as we know, no report on the possible association between blood pressure and C-peptide in PCOS women has been published. Furthermore, studies comparing C-peptide with other established clinical signs of T2DM and CVD in PCOS are lacking.

In a previous study, including non-PCOS subjects, C-peptide was highly associated with BMI and future T2DM development \[[@R10]\]. In non-diabetic, non-PCOS subjects, C-peptide was also associated with WC and body fat percentage, even after an adjustment for age, sex, insulin, and glucose levels \[[@R28]\]. Fasting C-peptide also showed a significant positive correlation with all of the anthropometric parameters in the present study. A positive correlation between C-peptide and BMI in PCOS was already reported \[[@R29]\], and C-peptide increased as BMI increased \[[@R30]\]. The mechanisms are not completely clear yet but it has been suggested that inflammatory cytokines play a significant role in patients with higher levels of C-peptide and a high BMI \[[@R30]\]. The strong correlations of C-peptide with BMI, WC and the W/H ratio found in the present study indicate that obesity is one of the major factors related to the increase in the β-cell function in PCOS women \[[@R31]\]. The possible effect of abdominal adipose tissue on β-cell function in other populations has been supported by experimental and clinical studies \[[@R30], [@R32]\].

Most of the dysglycemic biomarkers were well associated with C-peptide in the present study (P \< 0.001 for all). The fasting C-peptide/insulin ratio presented a weak correlation with C-peptide, and this weak correlation is a reflection of hepatic insulin extraction and the difference in the plasma half-lives of C-peptide and insulin. A good correlation between C-peptide, HOMA-IR, and serum insulin was previously demonstrated in PCOS patients \[[@R02]\]. The increase in C-peptide levels in PCOS indicates a worsened insulin resistance state with time \[[@R08]\]. In addition, C-peptide was strongly correlated with several biochemical markers of insulin resistance and fasting insulin levels in non-PCOS subjects \[[@R33]\]. The fasting C-peptide/fasting glucose molar ratio and the fasting β cell responsiveness index are considered to be the most valuable parameters for estimating β-cell function. In the current study, this index showed the strongest correlation with C-peptide (r = 0.967). The insulinogenic index, a surrogate for early insulin secretion was not correlated with C-peptide levels in the present study, but it tended to increase as in BMI increased (data not shown). In a previous study, this index was not different for any of the BMI groups \[[@R30]\], clearly suggesting that in PCOS insulin is not a good marker of β-cell dysfunction.

Even in the present study, C-peptide was strongly correlated with the different lipids (P ≤ 0.001), and the correlations were strongest with TG, VLDL-c and HDL-c. Consistent with the present study, higher levels of TC and TG, and lower levels of HDL-c were common findings in PCOS women, mainly in those with IGT \[[@R34]\]. Dyslipidemia has been closely related to obesity in PCOS \[[@R35]\]. Higher TG concentrations were previously found in overweight and obese PCOS patients \[[@R36]\]. In another study, TG was correlated with WC and BMI \[[@R37]\]. The LAP index was associated with C-peptide levels in the whole group of PCOS patients in the current study and the correlation of LAP, and HOMA-IR, were reported in recent studies as a good index to detect IR \[[@R38]\].

Among androgens, the total T, free T, and FAI were strongly and positively correlated with C-peptide levels. This positive correlation between C-peptide and the free and total T levels had already been demonstrated in PCOS \[[@R32]\], indicating a functional relationship between hyperandrogenemia and the functional capacity of pancreatic β cells. In a recent small study, no correlation was found between C-peptide and androgens in overweight and obese subjects \[[@R39]\], even though an association between insulin resistance and the hyperandrogenic state in PCOS has been described for decades \[[@R40]\]. Furthermore, it is well established that insulin facilitates androgen synthesis and secretion and decreases SHBG while increasing the free fraction of androgens \[[@R02]\].

C-peptide has been considered a better predictor of CVD and overall mortality than other known markers of IR and metabolic syndrome in non-PCOS subjects \[[@R33]\]. In addition, C-peptide levels may predict the future worsening of the other risk factors or the future development of T2DM and CVD \[[@R27]\]. A prediction model for C-peptide concentrations in PCOS patients was constructed in the present study, and it demonstrated that the C-peptide/glucose ratio, body weight, and FEI were the best biological markers of C-peptide concentrations in PCOS. Insulin levels were excluded in this model.

Despite the fact that the current study has revisited and expanded on the role of C-peptide as a metabolic marker of potential risk for T2DM and CVD in PCOS subjects, a few limitations have to be considered. The examination of only anthropometrical data and blood pressure as clinical parameters for the risk of T2DM and CVD should be considered. The influence of confounding obesity, other residual confounding factors, such as time of disease and life style were not controlled. The main concern with the imprecise androgen measurement in women was attenuated by providing extensive details regarding the imprecision and sensitivity of the assays used. Furthermore, recent comparisons between the current assays for sex steroids and liquid chromatography tandem have demonstrated good agreement between methods \[[@R41]\]. The strengths of this study include an objective exclusion of all of the hyperandrogenic conditions, eliminating some potential confounders and, demonstrating that most of variables worsen with adiposity.

The current study provides support for the hypothesis that the fasting C-peptide concentration is at least comparable to other already known predictors of T2DM and CVD and can be used as a sensitive biomarker in PCOS patients. These findings also made clear that, in PCOS women, obesity determines a higher demand in pancreatic β-cell function. A stepwise multiple regression analysis showed that the best independent predictors for C-peptide concentrations in PCOS were the fasting C-peptide/fasting glucose ratio, fasting glucose, body weight and FEI. Thus, this final model significantly improves the ability of the outcome variable C-peptide. In addition, the increase in C-peptide levels with age and anthropometrical parameters indicates a worsened β-cell function with time. Future studies, including objective vascular and endothelial examination, will be necessary to prove the utility of C-peptide as a simple marker of dysmetabolism and CVD risk in PCOS women.
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